1. Okamura JM, Miyagi JM, Terada K, et al. Potential clinical applications of C-reactive protein. J Clin Lab Anal. 1990;4(3):231-5.
2. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018;18:1-10.
3. Nakabayashi M, Adachi Y, Itazawa T, et al. MxA-based recognition of viral illness in febrile children by a whole blood assay. Pediatr Res. 2006;60:770-4.
4. Engelmann I, Dubos F, Lobert PE, et al. Diagnosis of viral infections using myxovirus resistance A (MxA). Pediatrics. 2015;135;e985-93.
5. Hatherill M, Tibby SM, Sykes K, et al. Diagnostic markers of infection: comparison of procalcitonin with C-reactive protein and leucocyte count. Arch Dis Child. 1999;81:417-21.
6. Andreola G, Bressan S, Callegaro S. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J. 2007;26(8):672-7.
7. Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child. 2001;84:332-6.
8. Korppi M, Kroger L. C-reactive protein viral and bacterial respiratory infection in children. Scand J Infect Dis. 1993;25(2):207-13.
9. Kawamura M, Kusano A, Furuya A, et al. New sandwich-type enzyme-linked immunosorbentent assay for human MxA protein in a whole blood using monoclonal antibodies against GTP-binding domain for recognition of viral infection. J Clin Lab Anal. 2012;26:174-83.
10. Gendrel D, Rayond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferonalpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. 1999;18(10):875-81.
11. Virkki R, Juven T, Rikalainen H, et al. Differentiation of bacterial and viral pneumonia in children. Thorax. 2002;57:438-41.
12. Self WH, Rosen J, Sharp SC, et al. Diagnostic accuracy of FebriDx: A rapid test to detect immune responses to viral and bacterial upper respiratory infections. J Clin Med. 2017;6(10):E94.
13. Davidson M. FebriDx point-of-care testing to guide antibiotic therapy for acute respiratory tract infection in UK primary care: A retrospective outcome analysis. J Infect Dis Preve Med. 2017;5:165.
14. Karim N, Ashraf MZ, Naseem M, et al. Utility of FebriDx in early identification of possible COVID-19 infection. Res Square. 2020;Epub ahead of print. https://www.researchsquare.com/article/rs-25802/v1
15. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. European Centre for Disease Prevention and Control. Accessed 19 June 2020.
16. Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19. J Infect. 2020;Epub ahead of print. doi: 10.1016/j.jinf.2020.06.051